Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Archives de pédiatrie
Volume 19, n° 6S1
pages H52-H53 (juin 2012)
Doi : 10.1016/S0929-693X(12)71136-3
TR9 – Endocrinopathies post- traitement du cancer

Conséquences osseuses des traitements anticancéreux

J.P. Salles
Unité d’endocrinologie, maladies osseuses, génétique, obésité et gynécologie de l’enfant, Hôpital des Enfants, CHU de Toulouse, INSERM UMR 1043 (CPTP), Mécanismes moléculaires de la cro issance, l’ostéogenèse et l’ostéolyse, biothérapies, Toulouse, France 


© 2012  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline